Skip to main content
Premium Trial:

Request an Annual Quote

DVS Sciences, Cytobank Partner on Data Software for Mass Cytometry

NEW YORK (GenomeWeb News) – DVS Sciences and Cytobank recently announced an agreement to co-develop and integrate a solution that automatically analyzes and manages large datasets generated by DVS' mass cytometry instruments.

Under the agreement the two firms will co-develop and integrate the solution called DVS Cytobank, which is being developed specifically for mass cytometry data. DVS has developed its mass cytometry platform called CyTOF to allow researchers to better understand the cellular dynamics of disease states, identify stem cells, and gain insight into other biological systems using metal conjugated antibodies bound to cells and mass spectrometry.

Software developed by Cytobank allows for the analysis and management of data generated by CyTOF using a cloud computing platform integrated with proprietary algorithms.

Joseph Victor, president and CEO of DVS, said in a statement, "The marriage of uniquely informative data acquired by our CyTOF instruments and reagents with the powerful capabilities of the Cytobank cloud based platform will be enabling for our researchers around the world as they analyze, manage, and share large amounts of multiparameter data."

An early version of DVS Cytobank will be released to DVS customers in August, with a formal release scheduled for November.

Financial and other terms of the deal were not disclosed.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.